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Cystic fibrosis is a genetic disease caused by mutation of the Cystic Fibrosis Transmembrane 
conductance Regulator (CFTR) protein. The disease is mostly associated with severe lung 
pathogenesis typically caused by infection by Pseudomonas aeruginosa. However, many patients 
also suffer from intestinal complications. The primary cause is pancreas insufficiency resulting in 
decreased release of digestive enzymes which is typically cured by enzyme replacement therapy. 
However, sticky mucus  formation and repetitive antibiotic treatment have a severe affect on the gut 
microcbiota. Several microbial studies indeed reported gut microbiota dysbiosis in patients with 
cystic fibrosis (CF).  However, the functional consequences of this phenomenon are poorly 
understood.  
 
We analysed faecal protein extracts from fifteen patients with CF that have pancreatic 
insufficiency and from their unaffected siblings by shotgun proteomics. Novel computational and 
statistical tools, among which the novel Unipept tool were introduced to evaluate changes in 
taxonomic composition and protein abundance. Faecal protein extracts from patients with CF were 
dominated by host proteins involved in inflammation and mucus formation. Taxonomic analysis of 
the microbial proteins confirmed the strong reduction of butyrate reducers such as Faecalibacterium 
prausnitzii and increase of Enterobacteriaceae, Ruminococcus gnavus and Clostridia species. Our 
work showed that faecal metaproteomics provides insights in intestinal dysbiosis, inflammation in 
patients with CF and can be used to monitor different disease markers in parallel.  
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